158 related articles for article (PubMed ID: 28985022)
1. Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-β-hydroxylase expression.
Shimoda M; Hori A; Wands JR; Tsunashima R; Naoi Y; Miyake T; Tanei T; Kagara N; Shimazu K; Kim SJ; Noguchi S
Cancer Sci; 2017 Dec; 108(12):2454-2461. PubMed ID: 28985022
[TBL] [Abstract][Full Text] [Related]
2. ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.
Lin Q; Chen X; Meng F; Ogawa K; Li M; Song R; Zhang S; Zhang Z; Kong X; Xu Q; He F; Bai X; Sun B; Hung MC; Liu L; Wands J; Dong X
Mol Cancer; 2019 Nov; 18(1):156. PubMed ID: 31694640
[TBL] [Abstract][Full Text] [Related]
3. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Relationship Between the Expression of Aspartate β-Hydroxylase and the Pathological Characteristics of Breast Cancer.
Zhang Y; Gao Y; Li Y; Zhang X; Xie H
Med Sci Monit; 2020 Dec; 26():e926752. PubMed ID: 33380715
[TBL] [Abstract][Full Text] [Related]
5. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
6. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
7. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
8. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Human Aspartyl (Asparaginyl) β-hydroxylase in NSCLC: Its Diagnostic Value by Means of Exosomes of Bronchoalveolar Lavage.
Zhu H; Liu H; Wen J; Yuan T; Ren G; Jiang Y; Yuan Y; Mei J; Yu Y; Li G
Appl Immunohistochem Mol Morphol; 2021 Nov-Dec 01; 29(10):720-727. PubMed ID: 34433181
[TBL] [Abstract][Full Text] [Related]
11. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Tomlinson DC; Knowles MA; Speirs V
Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
[TBL] [Abstract][Full Text] [Related]
14. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
15. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
[TBL] [Abstract][Full Text] [Related]
16. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of aspartate beta-hydroxylase in early breast cancer.
Barboro P; Rubagotti A; Poddine S; Grillo F; Mastracci L; Boccardo F
Int J Biol Markers; 2022 Sep; 37(3):328-335. PubMed ID: 35726161
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
19. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
[TBL] [Abstract][Full Text] [Related]
20. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
